Cite
Heynckes S, Gaebelein A, Haaker G, et al. Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme. Oncotarget. 2017;8(43):74170-74177doi: 10.18632/oncotarget.18819.
Heynckes, S., Gaebelein, A., Haaker, G., Grauvogel, J., Franco, P., Mader, I., Carro, M. S., Prinz, M., Delev, D., Schnell, O., & Heiland, D. H. (2017). Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme. Oncotarget, 8(43), 74170-74177. https://doi.org/10.18632/oncotarget.18819
Heynckes, Sabrina, et al. "Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme." Oncotarget vol. 8,43 (2017): 74170-74177. doi: https://doi.org/10.18632/oncotarget.18819
Heynckes S, Gaebelein A, Haaker G, Grauvogel J, Franco P, Mader I, Carro MS, Prinz M, Delev D, Schnell O, Heiland DH. Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme. Oncotarget. 2017 Jun 28;8(43):74170-74177. doi: 10.18632/oncotarget.18819. eCollection 2017 Sep 26. PMID: 29088776; PMCID: PMC5650331.
Copy
Download .nbib